BIOA BioAge Labs, Inc.

$8.49▼ -1.85% Healthcare Other
After hours $8.49▲ +0.00% Sep 11, 7:30 PM ET
Volume 672.1K Avg Volume (10D) 519.7K
Key Metrics & Fundamentals
Market Cap
$389.66M
P/E Ratio
–
Div Yield
–%
52W Range
4.68 - 25.96
% vs 50 MA
-44.28%
% vs 200 MA
-49.87%
RSI-14
29.2
MACD Histogram
+0.2500
Beta (1Y vs SPY)
1.76
Free Cash Flow
-$19.59M
Gross Rev
$2.45M
Gross Profit
$2.45M
EBITDA
-$25.83M
COGS
–
Operating Exp
$31.78M
Operating Income
-$29.33M
EBIT
-$29.33M
Pretax Income
-$26.10M
Net Income
-$26.10M
EPS (Diluted)
-0.58
Price & Volume History
Loading chart…
Recent News
BioAge Labs Doses First Patient in Phase 2 Trial of BGE-102 in Diabetic Macular Edema
MT Newswires · Sep 8, 2026 2:01 PM
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema
GlobeNewswire · Sep 8, 2026 12:00 PM
BioAge Labs to Present at Upcoming Investor Conferences
GlobeNewswire · Sep 2, 2026 12:00 PM
Number of shares and votes in BioArctic AB (publ) as of August 31, 2026
PR Newswire · Aug 31, 2026 3:57 PM
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
Zacks · Aug 6, 2026 12:35 AM
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · Aug 5, 2026 8:50 PM
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
Stocktwits · Jul 31, 2026 9:56 PM
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
PR Newswire · Jul 14, 2026 3:41 PM
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
PR Newswire · Jul 14, 2026 1:30 PM
Bioage Labs Insider Sold Shares Worth $1,576,752, According to a Recent SEC Filing
MT Newswires · Jul 1, 2026 8:34 PM
Financial Overview - Income Statement Quarterly

See BIOA's money flow as a full page

Social Sentiment
Avg +0.75 · 4 posts
Yahoo Finance featured my bullish thesis on $BIOA, via Insider Monkey
r/stocks · Dec 31, 2024
The post indicates a positive view on BIOA due to a Yahoo Finance feature, suggesting bullish sentiment.
positive +0.30
NewsDDTradeYahoo Finance featured my bullish thesis on $BIOA, via Insider Monkey
r/investing · Dec 31, 2024
The author is actively holding and considering adding to the stock based on positive news and recognition.
positive +0.80
DDNewsPriceTarget$BIOA
r/wallstreetbets · Oct 21, 2024
The post uses highly positive language ('🔥', 'going to be 🔥') and references the 'Ozempic and Wegovy wagon,' indicating strong bullish sentiment.
very_positive +1.00
NewsDiscussionTradePriceTarget$LLY backed partner BioAge ($BIOA) testing exercise mimetics together with GLP-1 weight loss drugs.
r/wallstreetbets · Sep 27, 2024
The post focuses on BioAge’s trial results and potential weight loss outcomes, driving significant enthusiasm.
very_positive +0.90
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙